Teach me in detail about disorders of sexual differentiation, everything from types , pathophysiology, diagnostic criterias , classification , management, use the latest guidelines, research , publications , be extremely thorough
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Teach me in detail about disorders of sexual differentiation, everything from types , pathophysiology, diagnostic criterias , classification , management, use the latest guidelines, research , publications , be extremely thorough
Reading File
This is a large, multidisciplinary topic. “Disorders of sex development” is now often described as differences of sex development (DSD), and current care centers on diagnosis, medical safety, fertility and pubertal care, psychosocial support, autonomy, and careful shared decision-making about any irreversible intervention.
- Terminology, embryology, and biology of sex development
- Modern classification
- Sex chromosome DSD
- 46,XX DSD
- 46,XY DSD
- Ovotesticular DSD and other complex presentations
- Individual conditions
- Turner, Klinefelter, mixed gonadal dysgenesis
- Congenital adrenal hyperplasia (CAH)
- Androgen insensitivity syndrome
- Gonadal dysgenesis, 5-alpha-reductase-2 deficiency, 17-beta-HSD3 deficiency
- Disorders of testosterone synthesis/action and Müllerian development
- Pathophysiology and genetics, including steroidogenesis and receptor/signaling defects
- Clinical presentations from newborn period through adolescence and adulthood
- Diagnostic evaluation
- Urgency assessment, including salt-wasting CAH
- History, examination, hormone testing, imaging, karyotype/chromosomal microarray, gene panels and sequencing
- Interpretation pitfalls and differential diagnosis
- Management
- Acute stabilization and hormone replacement
- Puberty induction, genital and gonadal management, fertility preservation
- Tumor-risk assessment and surveillance
- Mental health, family communication, consent, ethics, and transition to adult care
- Current guidelines and recent research, including areas of international disagreement and evidence gaps.
At a high level, DSD are congenital variations in chromosomal, gonadal, or anatomic sex development. They are not a single disease and should not be approached solely as a question of genital appearance. A specialized multidisciplinary team, ideally including pediatric endocrinology, urology/gynecology, genetics, psychology or psychiatry, neonatology, pathology, and adult-transition clinicians, is standard.
Which section should I teach in depth first?
Asking for Preferences
Choose the section to begin with. I will cover it in depth, with guideline-based diagnostic and management detail before moving to the next.
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.This is a large, multidisciplinary topic. “Disorders of sex development” is now often described as differences of sex development (DSD), and current care centers on diagnosis, medical safety, fertility and pubertal care, psychosocial support, autonomy, and careful shared decision-making about any irreversible intervention.
- Terminology, embryology, and biology of sex development
- Modern classification
- Sex chromosome DSD
- 46,XX DSD
- 46,XY DSD
- Ovotesticular DSD and other complex presentations
- Individual conditions
- Turner, Klinefelter, mixed gonadal dysgenesis
- Congenital adrenal hyperplasia (CAH)
- Androgen insensitivity syndrome
- Gonadal dysgenesis, 5-alpha-reductase-2 deficiency, 17-beta-HSD3 deficiency
- Disorders of testosterone synthesis/action and Müllerian development
- Pathophysiology and genetics, including steroidogenesis and receptor/signaling defects
- Clinical presentations from newborn period through adolescence and adulthood
- Diagnostic evaluation
- Urgency assessment, including salt-wasting CAH
- History, examination, hormone testing, imaging, karyotype/chromosomal microarray, gene panels and sequencing
- Interpretation pitfalls and differential diagnosis
- Management
- Acute stabilization and hormone replacement
- Puberty induction, genital and gonadal management, fertility preservation
- Tumor-risk assessment and surveillance
- Mental health, family communication, consent, ethics, and transition to adult care
- Current guidelines and recent research, including areas of international disagreement and evidence gaps.
At a high level, DSD are congenital variations in chromosomal, gonadal, or anatomic sex development. They are not a single disease and should not be approached solely as a question of genital appearance. A specialized multidisciplinary team, ideally including pediatric endocrinology, urology/gynecology, genetics, psychology or psychiatry, neonatology, pathology, and adult-transition clinicians, is standard.
Which section should I teach in depth first?Please choose where to begin:
- Classification and embryology of sex development
- 46,XX DSD, especially congenital adrenal hyperplasia
- 46,XY DSD, including androgen insensitivity and gonadal dysgenesis
- Diagnostic work-up: newborn emergency assessment, hormones, imaging, genetics
- Management: endocrine care, surgery, tumor risk, fertility, ethics, and psychosocial support
- Latest guidelines and recent research overview
Classification and embryology of sex development
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
"differences of sex development" AND classification
Searching the Web
2025 guideline differences disorders sex development classification embryology consensus
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading Web Page
https://www.nature.com/articles/s41574-018-0010-8
Searching Images
diagram embryologic sexual differentiation bipotential gonad SRY SOX9 AMH testosterone Mullerian Wolffian ducts external genitalia
Searching PubMed
"disorders of sex development" AND guideline
Finding Sources
Finding Sources
Reading Article
PMID: 41338999
Reading Article
PMID: 38573501
Finding Sources
1. What are differences/disorders of sex development?
Differences of sex development (DSD), also called disorders of sex development in much clinical literature, are congenital conditions in which development of one or more sex-related characteristics is atypical. These characteristics include:
- Chromosomal sex: for example 46,XX, 46,XY, 45,X, mosaics, or structural chromosome variants
- Gonadal sex: ovaries, testes, dysgenetic gonads, ovotestes, absent gonads
- Internal reproductive anatomy: Müllerian-derived structures or Wolffian-derived structures
- External genital anatomy
- Endocrine function: production, conversion, or action of sex steroids and anti-Müllerian hormone
- Pubertal and reproductive development
This is an umbrella category, not one diagnosis and not a synonym for ambiguous genitalia. A person may have a DSD with typical-appearing genitalia at birth and present later with delayed puberty, primary amenorrhea, infertility, inguinal hernia containing a gonad, or unexpected findings on genetic testing.
Terminology is personal and can be sensitive. Some people prefer “intersex,” some prefer their specific diagnosis, and some prefer DSD. In clinical documentation, use the individual’s preferred terms where possible. DSD is distinct from gender identity. Gender identity is a person’s internal experience of gender; DSD concerns congenital biology of sex development. Neither predicts the other.
The most current international approach remains multidisciplinary, lifespan-based, and autonomy-centered. Recent 2026 Japanese clinical guidelines explicitly define DSD as congenital discordance among chromosomal, gonadal, and anatomical sex characteristics, while emphasizing the limits of evidence and the need for individualized care (2026 practice guideline). A 2024 German multidisciplinary guideline similarly recommends deferring nonessential procedures and prioritizing the affected person’s self-determination (guideline update).
2. The developmental framework: sex development is not one switch
A useful way to understand DSD is to separate normal sex development into sequential but overlapping stages:
- Chromosomal and genetic setup
- Formation of the bipotential gonad
- Testis or ovarian determination
- Differentiation of internal reproductive ducts
- Differentiation of external genitalia
- Gonadal descent and later pubertal maturation
A variant at any stage can produce a different clinical phenotype.
The four biological domains
| Domain | Main question | Examples |
|---|---|---|
| Chromosomal sex | What sex-chromosome complement is present? | 46,XX; 46,XY; 45,X/46,XY mosaicism |
| Gonadal development | Did a testis, ovary, ovotestis, or dysgenetic gonad develop? | Complete gonadal dysgenesis; ovotesticular DSD |
| Internal anatomy | What happened to Müllerian and Wolffian ducts? | Uterus present or absent; vas deferens present or absent |
| Phenotypic/anatomical development | How did external genitalia and secondary sex characteristics develop? | Virilization in 46,XX CAH; undervirilization in 46,XY DSD |
These domains can be discordant. For example, a person with complete androgen insensitivity syndrome can have a 46,XY karyotype and testes that produce AMH and testosterone, no uterus because AMH is effective, and typically female external genitalia because androgen signaling is ineffective.
3. Embryology: the timeline
Gestational ages vary slightly by source and by whether age is counted from fertilization or last menstrual period. The sequence matters more than exact day counts.
| Approximate fetal stage | Major event | Why it matters clinically |
|---|---|---|
| Weeks 4-5 | Urogenital ridge forms; primordial germ cells migrate toward future gonads | Early disruption can affect both gonads and kidneys |
| Weeks 5-6 | Indifferent or bipotential gonad develops | XX and XY embryos have similar gonadal structures initially |
| Weeks 6-7 onward | Testis-determining or ovary-promoting networks become dominant | Disruption causes gonadal dysgenesis, sex reversal, or ovotesticular development |
| Weeks 7-12 | Testicular AMH and testosterone drive internal duct differentiation | Failure produces persistence or loss of expected ducts |
| Weeks 8-14 | DHT-dependent external genital masculinization | Defects cause undervirilized external genitalia in 46,XY fetuses |
| Late fetal life and infancy | “Mini-puberty” activation of the hypothalamic-pituitary-gonadal axis | Helps evaluate testicular function in infants |
| Puberty | Reactivation of reproductive endocrine axis | DSD may first present as absent, incomplete, or atypical puberty |
4. Stage 1: chromosomal sex and the genetic starting point
At fertilization, an oocyte normally contributes an X chromosome and the sperm contributes either X or Y. This commonly produces 46,XX or 46,XY embryos, but sex-chromosome variation is possible.
Chromosomes matter, but they do not fully determine anatomy. Examples:
- 46,XX testicular DSD can occur when testis-determining material, commonly including SRY, is translocated to an X chromosome or autosome.
- 46,XY complete gonadal dysgenesis can arise from pathogenic variants in genes required for testis development, including SRY, SOX9, NR5A1, WT1, DHH, MAP3K1, and others.
- 45,X/46,XY mosaicism can produce a broad spectrum, from typical male anatomy to Turner-like features, mixed gonadal dysgenesis, or atypical genitalia.
- Structural changes and copy-number variation involving key regulatory regions, not only coding genes, can alter development.
Thus, a karyotype is an important starting point, not a complete diagnosis.
5. Stage 2: formation of the bipotential gonad
The gonads arise from the genital or gonadal ridge, on the medial side of the developing mesonephros. This close embryologic relationship explains why certain DSD-associated syndromes have renal anomalies.
Before sex-specific differentiation, the gonad is capable of becoming either an ovary or a testis. Essential early developmental regulators include:
- WT1
- NR5A1, also called steroidogenic factor 1 or SF-1
- GATA4
- ZFPM2/FOG2
- CBX2
- LHX9
- EMX2
Failure in early gonadal formation can lead to gonadal dysgenesis, impaired steroid production, infertility, and sometimes associated adrenal, renal, cardiac, or syndromic disease.
Primordial germ cells
Primordial germ cells originate outside the gonad and migrate into the genital ridge. They later become:
- Oogonia/oocytes in ovaries
- Spermatogonia/sperm in testes
Normal interaction between germ cells and gonadal somatic cells is necessary for mature gonadal structure and fertility. Gonadal dysgenesis can impair this environment and, in certain settings, increase risk of germ-cell neoplasia.
6. Stage 3: testis determination
The testis pathway
In many 46,XY embryos, expression of SRY in a narrow developmental window activates a testis-promoting network. SRY is on the short arm of the Y chromosome and encodes a transcription factor, but it does not work alone.
The central downstream regulator is SOX9.
Simplified pathway
46,XY embryo with functional testis-determining pathway
↓
SRY expression in the bipotential gonad
↓
Upregulation of SOX9
↓
Sertoli-cell differentiation and testis-cord formation
↓
AMH production by Sertoli cells
↓
Müllerian duct regression
SOX9 and testicular paracrine signals
↓
Leydig-cell differentiation
↓
Testosterone production
↓
Wolffian duct maintenance and differentiation
Other important testis-promoting factors include:
- SOX9: central determinant of Sertoli-cell identity and testis-cord development
- FGF9: reinforces SOX9 and suppresses ovarian pathway activity
- PGD2
- DHH: contributes to Leydig-cell development
- DMRT1: important for maintenance of testicular identity
- NR5A1/SF-1
- WT1
- GATA4-ZFPM2
The biological idea is not that “male development happens automatically.” Testis and ovarian pathways actively oppose and suppress one another. The balance must be established at the correct time and then maintained throughout life.
Consequences of testis-pathway disruption
In a 46,XY fetus, reduced or absent testis determination may cause:
- complete or partial gonadal dysgenesis
- dysgenetic or streak gonads
- reduced AMH production, resulting in a uterus and fallopian tubes
- reduced testosterone production, resulting in absent or underdeveloped Wolffian structures
- female-typical, ambiguous, or undervirilized external genitalia
- later absent puberty, infertility, and possibly elevated gonadal tumor risk depending on the diagnosis and gonadal location
Important examples include:
- SRY pathogenic variants or deletions
- SOX9 pathogenic variants or regulatory-region disruption
- NR5A1 pathogenic variants
- WT1-related disease, including Denys-Drash and Frasier syndromes
- MAP3K1 gain-of-function variants
- DHH variants
- 9p deletions affecting DMRT1
The medical-textbook summary of this gene network describes SF-1 and WT1 as essential to gonadal-ridge development and notes that SRY-induced SOX9 promotes testis formation, whereas WNT4/beta-catenin and related signals inhibit testis formation and favor ovarian development. This framework also aligns with the recent review of the genetic control of sex development (Nature Reviews Urology review).
7. Stage 4: ovarian determination and maintenance
The ovarian pathway
Ovarian development is an active process. It is not simply the absence of SRY or testosterone.
Key ovarian-promoting and testis-suppressing factors include:
- WNT4
- RSPO1
- beta-catenin pathway
- FOXL2
- BMP2
- FST/follistatin
- NR2F2
- DAX1/NR0B1, in some contexts
Simplified pathway
46,XX embryo with intact ovary-promoting pathway
↓
WNT4 + RSPO1 activation
↓
Beta-catenin signaling
↓
Suppression of SOX9/testis-cord program
↓
Ovarian somatic-cell differentiation
↓
Follicle development and ovarian maintenance
FOXL2 is especially important for ovarian maintenance. In animal and cellular models, loss of ovarian-maintenance signaling can permit activation of testis-associated pathways after initial ovarian differentiation.
Consequences of ovarian-pathway disruption
Disruption may produce:
- 46,XX gonadal dysgenesis or primary ovarian insufficiency
- 46,XX testicular DSD
- ovotesticular DSD
- variable virilization
- absent or atypical Müllerian structures in selected conditions
Examples:
- RSPO1 deficiency: can be associated with 46,XX testicular or ovotesticular development and palmoplantar hyperkeratosis
- WNT4-related conditions: can be associated with Müllerian abnormalities and hyperandrogenic features
- FOXL2 pathogenic variants: classically associated with blepharophimosis-ptosis-epicanthus inversus syndrome and primary ovarian insufficiency
- NR5A1 variants: may produce diverse XX or XY gonadal and reproductive phenotypes
A key limitation in current research is that the genetic explanation for 46,XX DSD, excluding congenital adrenal hyperplasia, remains less complete than for many 46,XY DSD presentations (genetics review).
8. Stage 5: internal reproductive duct development
At the indifferent stage, embryos have both paired duct systems.
| Embryologic structure | Alternative name | Typical fate if it persists |
|---|---|---|
| Müllerian ducts | Paramesonephric ducts | Fallopian tubes, uterus, cervix, upper vagina |
| Wolffian ducts | Mesonephric ducts | Epididymis, vas deferens, seminal vesicles, ejaculatory ducts |
Sertoli cells, AMH, and Müllerian regression
In a functioning fetal testis, Sertoli cells secrete anti-Müllerian hormone (AMH), also called Müllerian-inhibiting substance.
AMH acts locally through its receptor system to cause regression of Müllerian structures. This normally begins early in fetal development.
Failure of AMH signaling in a 46,XY individual may result in a uterus and fallopian tubes despite testes and otherwise male-typical internal structures. This is persistent Müllerian duct syndrome (PMDS), caused by pathogenic variants in:
- AMH
- AMHR2, the AMH type-2 receptor
Leydig cells, testosterone, and Wolffian differentiation
Fetal Leydig cells produce testosterone. Testosterone stabilizes and masculinizes the Wolffian ducts, producing:
- epididymis
- vas deferens
- seminal vesicles
- ejaculatory ducts
If testosterone production is absent or inadequate, or androgen receptor action is impaired, Wolffian structures regress.
Clinical interpretation: uterus and Wolffian structures are biological clues
| Finding | Suggests, but does not prove |
|---|---|
| Uterus present in a 46,XY individual | Insufficient AMH production/action, commonly dysgenetic gonads or PMDS |
| Uterus absent in a 46,XY individual with female external genitalia | Functional fetal AMH, as in complete androgen insensitivity syndrome or some testosterone-biosynthesis defects |
| Wolffian structures present | At least some fetal testosterone effect |
| Wolffian structures absent | Low fetal testosterone, impaired androgen action, or developmental disruption |
Textbook physiology describes this division clearly: Sertoli-cell AMH causes Müllerian regression, whereas Leydig-cell testosterone supports Wolffian differentiation. In the absence of both, Müllerian structures persist and Wolffian ducts regress.
9. Stage 6: external genital development and the role of DHT
The external genitalia also begin from common, indifferent structures:
| Indifferent structure | Typical androgen-dependent masculinized derivative | Typical development without substantial androgen effect |
|---|---|---|
| Genital tubercle | Glans penis and shaft | Clitoris |
| Urogenital folds | Ventral penile urethra and penile shaft tissue | Labia minora |
| Labioscrotal swellings | Scrotum | Labia majora |
| Urogenital sinus | Prostatic urethra and part of male urethra | Lower vagina and vestibule |
DHT is central
Although testosterone supports Wolffian duct development, dihydrotestosterone (DHT) is the major androgen required for virilization of the external genitalia, prostate, and penile urethra.
The conversion is:
Testosterone
↓ 5-alpha-reductase type 2, encoded by SRD5A2
Dihydrotestosterone (DHT)
↓
Androgen receptor activation in target tissues
↓
Masculinization of external genitalia and prostate
External genital differentiation largely occurs during the first trimester. Disruption during this window can cause a spectrum from mild hypospadias to markedly undervirilized or female-typical external genitalia in a 46,XY infant.
Examples of DHT-androgen pathway disorders
| Defect | Internal anatomy | External genitalia at birth |
|---|---|---|
| 5-alpha-reductase type 2 deficiency | Wolffian structures usually develop because testosterone is present | Variable undervirilization because DHT generation is low |
| Complete androgen insensitivity syndrome | No uterus due to AMH; Wolffian structures usually absent because androgen receptor action is ineffective | Usually female-typical |
| Partial androgen insensitivity syndrome | Variable | Variable undervirilization |
| Testosterone biosynthesis defects | AMH may cause absent uterus if Sertoli cells function; Wolffian structures vary | Variable undervirilization |
10. The default pathway is more nuanced than “female by default”
A simplified teaching statement says that female internal and external genital development occurs “by default” when AMH, testosterone, and DHT are absent. This is only partly useful.
It is true that:
- Müllerian ducts persist without AMH.
- Wolffian ducts regress without testosterone.
- External genitalia do not masculinize without adequate androgen action.
However, ovarian development itself requires active gene networks, particularly WNT4-RSPO1-beta-catenin and FOXL2-associated signaling. Therefore, the more accurate statement is:
Development of female-typical internal and external anatomy occurs in the absence of fetal testicular hormones, while ovarian determination and maintenance require an active genetic program.
11. The 2006 Chicago classification and current use
The 2006 international consensus replaced older terms such as “intersex,” “pseudohermaphroditism,” and “true hermaphroditism” in clinical classification. Some older terms appear in historic literature but are generally avoided in present-day professional communication.
The traditional clinically useful DSD classification has three main categories based on chromosomal complement:
- Sex chromosome DSD
- 46,XX DSD
- 46,XY DSD
This remains the organizing framework in modern reviews and guidelines (international consensus statement).
A. Sex chromosome DSD
These involve an atypical number or structure of sex chromosomes, often with mosaicism.
Examples include:
- 45,X and variants of Turner syndrome
- 47,XXY and variants of Klinefelter syndrome
- 45,X/46,XX mosaicism
- 45,X/46,XY mosaicism
- 46,XX/46,XY chimerism
- structural X or Y chromosome variants, including Y material translocation or deletion
Clinical range is very broad. Depending on the condition, concerns may include growth, cardiac or renal anomalies, gonadal dysgenesis, pubertal failure, infertility, androgen deficiency, and variable gonadal tumor risk.
45,X/46,XY mosaicism is particularly important because phenotype can range from female-typical genitalia with Turner features to atypical genitalia or male-typical anatomy. The degree and distribution of mosaicism differ across tissues, so blood karyotype alone may not perfectly represent gonadal tissue.
B. 46,XX DSD
A person has a 46,XX karyotype but atypical gonadal, hormonal, internal, or external sex development.
Main subgroups:
1. Disorders of gonadal development
- 46,XX gonadal dysgenesis
- 46,XX testicular DSD, often due to translocated SRY
- Ovotesticular DSD
- Gene-related conditions involving RSPO1, WNT4, NR5A1, WT1, SOX9 duplication, or other genetic mechanisms
2. Androgen excess or androgen exposure
- Congenital adrenal hyperplasia, especially 21-hydroxylase deficiency: the most frequent cause of 46,XX DSD
- Placental aromatase deficiency
- Maternal androgen exposure, including maternal tumors or exogenous androgenic drugs
- Rare fetal steroid-metabolism disorders
In 46,XX CAH, ovaries and Müllerian structures are generally present because AMH is absent. Prenatal excess adrenal androgens can virilize external genitalia to varying degrees.
C. 46,XY DSD
A person has a 46,XY karyotype with atypical testicular development, androgen production, androgen conversion, androgen action, or related anatomy.
Main subgroups:
1. Disorders of testicular development
- Complete or partial gonadal dysgenesis
- SRY, SOX9, NR5A1, WT1, DHH, MAP3K1, DMRT1, and related gene disorders
- Testicular regression syndrome
- Ovotesticular DSD
2. Disorders of androgen synthesis or metabolism
- Leydig-cell hypoplasia, often involving LHCGR
- Steroidogenic acute regulatory protein defects
- CYP11A1 deficiency
- 17-alpha-hydroxylase/17,20-lyase deficiency, CYP17A1
- 3-beta-hydroxysteroid dehydrogenase type 2 deficiency, HSD3B2
- 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, HSD17B3
- 5-alpha-reductase type 2 deficiency, SRD5A2
3. Disorders of androgen action
- Complete androgen insensitivity syndrome
- Partial androgen insensitivity syndrome
- Mild androgen insensitivity syndrome
These result from pathogenic variants in AR, the androgen receptor gene, or very rarely defects in related androgen-signaling mechanisms.
4. Disorders of AMH synthesis or action
- Persistent Müllerian duct syndrome due to AMH or AMHR2 defects
This category is often considered separately because the affected person may have otherwise typical testosterone-dependent virilization.
12. Why classification is useful, and where it fails
The three-group karyotype classification is valuable because it directs urgent testing and differential diagnosis. For example:
- A 46,XX newborn with virilization should prompt urgent consideration of CAH.
- A 46,XY newborn with atypical genitalia requires assessment of testicular function, androgen production/action, and possible gonadal dysgenesis.
- A person with sex-chromosome mosaicism requires syndrome-specific evaluation, including gonadal-risk assessment where Y-chromosome material is present.
However, it has limitations:
- It is not mechanistic enough. Two people with 46,XY DSD can have entirely different diagnoses, risks, fertility potential, and management.
- It does not fully capture mosaicism. Karyotype can differ between blood, skin, and gonadal tissue.
- It can underrepresent syndromic disease. A DSD may be one feature of renal, adrenal, skeletal, cardiac, neurologic, or metabolic disease.
- It does not determine gender identity or sex of rearing.
- It does not provide a management plan. Diagnosis-specific counseling is required.
Therefore, a modern description should include both the umbrella category and the precise diagnosis when known. For example:
“46,XY DSD due to pathogenic AR variant causing complete androgen insensitivity syndrome.”
is much more informative than simply “46,XY DSD.”
13. A mechanism-based classification that complements karyotype
For learning and clinical reasoning, add a second classification layer based on where development diverged.
| Mechanism | Typical examples | Core developmental consequence |
|---|---|---|
| Chromosomal variation/mosaicism | 45,X/46,XY; 47,XXY | Altered dosage or mosaic distribution of sex-chromosome genes |
| Bipotential gonad formation defect | WT1, NR5A1, GATA4 disorders | Gonadal dysgenesis or impaired steroidogenesis |
| Testis determination defect | SRY, SOX9, DHH, MAP3K1 | Partial or complete 46,XY gonadal dysgenesis |
| Ovary determination/maintenance defect | RSPO1, WNT4, FOXL2 | 46,XX gonadal variation, ovarian insufficiency, or testicular/ovotesticular tissue |
| AMH synthesis/action defect | AMH, AMHR2 | Persistence of Müllerian structures in 46,XY individual |
| Testosterone synthesis defect | HSD17B3, CYP17A1, LHCGR | Reduced Wolffian differentiation and undervirilization |
| Testosterone-to-DHT conversion defect | SRD5A2 | Reduced external genital/prostatic virilization |
| Androgen receptor defect | AR variants | Reduced or absent androgen response despite circulating androgen |
| Excess androgen in 46,XX fetus | CAH, aromatase deficiency, maternal androgen exposure | External genital virilization, with uterus and ovaries generally present |
| Müllerian-development anomaly | MRKH spectrum, Mayer-Rokitansky-Küster-Hauser syndrome | Uterovaginal absence/hypoplasia, usually with typical ovarian function |
MRKH is often discussed alongside DSD because it concerns congenital reproductive-tract development, but classification may vary between systems. It is not a disorder of androgenization or gonadal sex determination in the same sense as CAH or androgen insensitivity.
14. High-yield embryology links to clinical phenotypes
| Clinical phenotype | Likely developmental inference |
|---|---|
| 46,XX infant with virilized external genitalia and uterus | Prenatal androgen excess, especially CAH |
| 46,XY infant with uterus and atypical/female-typical genitalia | Testicular dysgenesis or inadequate AMH production/action |
| 46,XY person with no uterus, female-typical external genitalia, testes | Consider complete androgen insensitivity, testosterone synthesis defect, or 5-alpha-reductase deficiency; distinguish hormonally/genetically |
| 46,XY male-typical external genitalia with uterus found during orchiopexy | Consider persistent Müllerian duct syndrome |
| 46,XY person with absent/poor puberty and streak gonads | Consider complete gonadal dysgenesis |
| 46,XX person with absent puberty and high gonadotropins | Consider primary ovarian insufficiency or 46,XX gonadal dysgenesis |
| Atypical genitalia plus renal disease | Consider syndromic gonadal dysgenesis, including WT1-related disease |
These are diagnostic patterns, not diagnostic criteria. Definitive diagnosis requires a structured clinical, endocrine, genetic, and imaging evaluation.
15. Core takeaways
- Sex development has multiple independent components. Chromosomes, gonads, hormones, ducts, external anatomy, puberty, fertility, and gender identity must not be treated as interchangeable.
- The bipotential gonad is the developmental crossroads. Testis development requires a timely SRY-SOX9-centered network; ovarian development requires active WNT4-RSPO1-beta-catenin and FOXL2-associated networks.
- Sertoli cells and Leydig cells have different developmental roles.
- Sertoli cells make AMH, leading to Müllerian regression.
- Leydig cells make testosterone, supporting Wolffian ducts.
- DHT, not testosterone alone, is particularly important for external genital masculinization.
- The usual clinical classification is sex chromosome DSD, 46,XX DSD, and 46,XY DSD, but a complete diagnosis should also specify the developmental mechanism and genetic etiology.
- Present-day care rejects appearance-only decision-making. It prioritizes medical safety, diagnostic precision, psychological support, fertility considerations, and the person’s evolving autonomy.
The next logical section is 46,XX DSD and congenital adrenal hyperplasia, because it applies the embryology directly and includes an important neonatal emergency.
This is a shared conversation. Sign in to Orris to start your own chat.